Some bladder cancer patients benefit from Roche therapy
Tue, Jun 07, 2016 - 5:50 AM
Results of the mid-stage trial could help make the case that Roche's drug should become the first option therapy of choice for patients with metastatic bladder cancer, says a researcher leading the study.
A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.
Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become...